195 related articles for article (PubMed ID: 26170162)
1. His-tagged norovirus-like particles: A versatile platform for cellular delivery and surface display.
Koho T; Ihalainen TO; Stark M; Uusi-Kerttula H; Wieneke R; Rahikainen R; Blazevic V; Marjomäki V; Tampé R; Kulomaa MS; Hytönen VP
Eur J Pharm Biopharm; 2015 Oct; 96():22-31. PubMed ID: 26170162
[TBL] [Abstract][Full Text] [Related]
2. Structural heterogeneity of a human norovirus vaccine candidate.
Devant JM; Hansman GS
Virology; 2021 Jan; 553():23-34. PubMed ID: 33202318
[TBL] [Abstract][Full Text] [Related]
3. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
4. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
[TBL] [Abstract][Full Text] [Related]
5. Virus-like particles produced in plants as potential vaccines.
Scotti N; Rybicki EP
Expert Rev Vaccines; 2013 Feb; 12(2):211-24. PubMed ID: 23414411
[TBL] [Abstract][Full Text] [Related]
6. Genotype considerations for virus-like particle-based bivalent norovirus vaccine composition.
Malm M; Tamminen K; Lappalainen S; Uusi-Kerttula H; Vesikari T; Blazevic V
Clin Vaccine Immunol; 2015 Jun; 22(6):656-63. PubMed ID: 25903355
[TBL] [Abstract][Full Text] [Related]
7. Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform.
O'Rourke JP; Peabody DS; Chackerian B
Curr Opin Virol; 2015 Apr; 11():76-82. PubMed ID: 25829254
[TBL] [Abstract][Full Text] [Related]
8. Plant-derived virus-like particles as vaccines.
Chen Q; Lai H
Hum Vaccin Immunother; 2013 Jan; 9(1):26-49. PubMed ID: 22995837
[TBL] [Abstract][Full Text] [Related]
9. Characterization of porcine circovirus type 2 (PCV2) capsid particle assembly and its application to virus-like particle vaccine development.
Wu PC; Lin WL; Wu CM; Chi JN; Chien MS; Huang C
Appl Microbiol Biotechnol; 2012 Sep; 95(6):1501-7. PubMed ID: 22526782
[TBL] [Abstract][Full Text] [Related]
10. Self-assembly of virus-like particles of canine parvovirus capsid protein expressed from Escherichia coli and application as virus-like particle vaccine.
Xu J; Guo HC; Wei YQ; Dong H; Han SC; Ao D; Sun DH; Wang HM; Cao SZ; Sun SQ
Appl Microbiol Biotechnol; 2014 Apr; 98(8):3529-38. PubMed ID: 24413974
[TBL] [Abstract][Full Text] [Related]
11. SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier.
Kawano M; Matsui M; Handa H
Expert Rev Vaccines; 2013 Feb; 12(2):199-210. PubMed ID: 23414410
[TBL] [Abstract][Full Text] [Related]
12. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.
Zhang X; Xin L; Li S; Fang M; Zhang J; Xia N; Zhao Q
Hum Vaccin Immunother; 2015; 11(5):1277-92. PubMed ID: 25751641
[TBL] [Abstract][Full Text] [Related]
14. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.
Pleckaityte M; Bremer CM; Gedvilaite A; Kucinskaite-Kodze I; Glebe D; Zvirbliene A
BMC Biotechnol; 2015 Sep; 15():85. PubMed ID: 26370129
[TBL] [Abstract][Full Text] [Related]
15. Production of Norovirus VLPs to size homogeneity.
Huo Y; Wan X; Wang Z; Meng S; Shen S
Virus Res; 2015 Jun; 204():1-5. PubMed ID: 25892715
[TBL] [Abstract][Full Text] [Related]
16. Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines.
Lei X; Cai X; Yang Y
Expert Rev Vaccines; 2020 Mar; 19(3):235-246. PubMed ID: 32133886
[No Abstract] [Full Text] [Related]
17. Alphavirus capsid proteins self-assemble into core-like particles in insect cells: A promising platform for nanoparticle vaccine development.
Hikke MC; Geertsema C; Wu V; Metz SW; van Lent JW; Vlak JM; Pijlman GP
Biotechnol J; 2016 Feb; 11(2):266-73. PubMed ID: 26287127
[TBL] [Abstract][Full Text] [Related]
18. Production and biomedical applications of virus-like particles derived from polyomaviruses.
Teunissen EA; de Raad M; Mastrobattista E
J Control Release; 2013 Nov; 172(1):305-321. PubMed ID: 23999392
[TBL] [Abstract][Full Text] [Related]
19. Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.
Lu Y; Chan W; Ko BY; VanLang CC; Swartz JR
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12360-5. PubMed ID: 26392546
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Cowpea chlorotic mottle virus-like particles as scaffold for epitope presentations.
Hassani-Mehraban A; Creutzburg S; van Heereveld L; Kormelink R
BMC Biotechnol; 2015 Aug; 15():80. PubMed ID: 26311254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
